Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adult ADHD Self-Report Scale

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Adult ADHD Self-Report Scale. Displaying page 1 of 1.
    EudraCT Number: 2015-000488-15 Sponsor Protocol Number: 3.0 Start Date*: 2015-10-07
    Sponsor Name:University of Leipzig
    Full Title: Vigilance regulation as predictor of response to Psychostimulants in adult patients with ADHD
    Medical condition: Attention deficit-hyperactivity disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002111-82 Sponsor Protocol Number: 42603ATT3013 Start Date*: 2007-10-24
    Sponsor Name:Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROSĀ® methylphenidate (54 and 72 mg/day) i...
    Medical condition: Attention Deficit-Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) NL (Completed) DK (Completed) FI (Completed) BE (Completed) GB (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004710-95 Sponsor Protocol Number: REPAS161118 Start Date*: 2018-02-07
    Sponsor Name:Beroendecentrum Stockholm
    Full Title: Extended-release injectable suspension naltrexone (XR-NTX) as an adjunt pharmacotherapy for prevention of substance use in patients with SUD who are currently in treatment for ADHD: A multicenter r...
    Medical condition: Amphetamine dependence and ADHD (Attention-Deficit/Hyperactivity Disorder)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001098-55 Sponsor Protocol Number: MMED007 Start Date*: 2021-11-24
    Sponsor Name:Mind Medicine, Inc.
    Full Title: Safety and efficacy of repeated low dose D-lysergic acid diethylamide (LSD) D-Tartrate (MM-120) as treatment for ADHD in adults: a multi-center, randomized, double- blind, placebo-controlled Phase ...
    Medical condition: Attention-Deficit/Hyperactivity Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004037-18 Sponsor Protocol Number: 42603ATT3004 Start Date*: 2006-03-10
    Sponsor Name:Janssen-Cilag Medical Affairs EMEA
    Full Title: An Open Label, Multicentre Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity Disor...
    Medical condition: Attention Deficit-Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003735 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002002-20 Sponsor Protocol Number: 2014METAL1 Start Date*: 2015-06-10
    Sponsor Name:UMCG
    Full Title: A multicentre randomized double-blind placebo controlled discontinuation trial of methylphenidate
    Medical condition: attention-deficit/hyperactivity disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000730-37 Sponsor Protocol Number: 42603ATT3002 Start Date*: 2005-02-07
    Sponsor Name:Janssen-Cilag Medical Affairs EMEA
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 a...
    Medical condition: Attention Deficit Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    10003731
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) CZ (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-007672-41 Sponsor Protocol Number: Protocol B4Z-MC-LYDO Start Date*: 2008-12-23
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol B4Z-MC-LYDO(b) Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Cont...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) FR (Completed) PT (Completed) SE (Completed) AT (Completed) FI (Completed) BE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA